Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;23(2):509-518.
doi: 10.4314/ahs.v23i2.59.

The epidemiology and characteristics of patients with diabetes with or without NASH: a systematic review

Affiliations

The epidemiology and characteristics of patients with diabetes with or without NASH: a systematic review

Khaled K Aldossari. Afr Health Sci. 2023 Jun.

Abstract

Introduction: NASH or "Non-alcoholic Steatohepatitis" is related to non-alcoholic fatty liver disease (NAFLD). The simultaneous occurrence of NASH and type 2 diabetes is common. However, only a limited number of studies have focused on the characteristics of patients with diabetes with or without NASH.

Objectives: This systematic review summarises epidemiological evidence related to the prevalence and characteristics of NASH in patients with diabetes.

Methods: Different electronic databases PubMed, Scopus, and Google Scholar were searched for the published articles. Original studies conducted in patients with diabetes published in English were included in this review.

Results: Thirteen studies were eligible for inclusion in this review. In patients with diabetes, increased BMI, overweight/obesity, increased HbA1c, increased serum cholesterol, and elevated liver enzyme levels have been strongly linked with NASH. Other significant characteristics include increasing age, being female, race(white), low HDL, metformin use, increased ferritin, and increased albumin levels. The prevalence of NASH ranged from 12% to 93.8%, the highest percentage was found in studies in Romania (87.1), and lowest in studies in India (12.5).

Conclusion: The incidence of NASH increases with age. Gender differences as a risk factor for NASH still need to be fully understood. This systematic review provides insight and strong indication to all patients with diabetes to visit hepatologists and screen for fatty liver disease. If steatosis is found on baseline ultrasound, a liver biopsy should be performed for timely management. At present, no NAFLD/NASH-specific medication on the market helps in treating the disease. New development of the drugs and ongoing research is important for the cure and treatment of NASH, with specific attention being provided to involve populations at high-risk.

Keywords: NAFLD; NASH; diabetes mellitus; fatty liver; liver disease; non-alcoholic steatohepatitis; systematic review.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA Flow chart summarizing the selection of articles for systematic review

Similar articles

Cited by

References

    1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature reviews Gastroenterology & hepatology. 2018;15(1):11–20. - PubMed
    1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature reviews Gastroenterology & hepatology. 2013;10(6):330. - PubMed
    1. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of hepatology. 2017;67(6):1265–1273. - PubMed
    1. Ahmed A, Wong RJ, Harrison SA. Non-alcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol. 2015;13(12):2062–2070. - PubMed
    1. Yki-Järvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD) Diabetologia. 2016;59(6):1104–1111. - PubMed

Publication types

LinkOut - more resources